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During HIV type 1 (HIV-1) entry, trimers of viral gp120 proteins attach to CD4 
molecules and to CCR5 or CXCR4 coreceptors on the target cell. A virus is defined as 
R5 tropic if it uses CCR5 coreceptors and X4 tropic if it uses CXCR4. In addition to the 
difference in coreceptor usage, R5 and X4 tropic viruses display other phenotypic 
differences. R5 virus dominates in early infection even when recipients are co-infected 
with both viral tropisms. As the disease progresses, the virus evolves and a tropism 
switch from R5 to X4 occurs in approximately 50% of patients. This study aims to more 
fully elucidate the mechanisms underlying the phenotypic differences between X4 and 
R5 virus.  
The stoichiometric parameters associated with HIV-1 target cell entry remain 
unclear and may differ depending on coreceptor usage. Important unanswered questions 
include: how many viral envelope trimers (or spikes) must attach to CD4 molecules, how 
many must bind coreceptors, and how many functional gp120 subunits per envelope 
trimer are required for entry? To answer these questions we performed single round 
infectivity assays with chimeric viruses.  Theoretical relative infectivity curves were 
generated using mathematical models and compared to the experimental curves. Using 
this methodology we determined that HIV-1 entry requires only a small number (one or 
two) of functional envelope spikes. Our data indicate that an individual virion has 
between one and three envelope spikes on its surface that are both functional and able to 
simultaneously contact a target cell. In addition, our analysis shows that trimeric 
envelope spikes may function with fewer than three active gp120 subunits. However, our 
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analysis of the entry mechanism indicates that there is no major difference in the 
stoichiometric requirements for CCR5 versus CXCR4-mediated HIV-1 entry into host 
cells.  
To investigate whether factors outside of viral entry machinery differentially 
affect the fitness of R5 and X4 tropic viruses, we used in vitro techniques to assay 
infection rates, target cell availability, viral burst size, and the potential negative pressure 
of the cytotoxic lymphocyte (CTL) response. Our study indicates that R5 virus has a 
kinetic advantage over X4 virus replication. Our results show that neither CTL 
suppression nor burst size correlates to tropism and thus is unlikely to play a role in early 
R5 viral dominance. Contrary to what is seen in newly infected patients, we saw 
consistently higher rates of infection with X4 virus. Viral growth modeling indicates that 
target cell availability in our in vitro system is responsible for this apparent X4 
replication advantage. Infection rate constants for X4 and R5 virus, which are influenced 
by infection rate, burst size, and target cell availability, indicate that R5 virus has a more 
than two fold replication advantage over some of the X4 viral isolates. If target cell 
availability during early infection does not overwhelmingly favor X4 growth, then this 
kinetic difference could explain R5’s initial dominance.  
Overall, our data supports the hypothesis that credits replication rate and target 
cell availability for dominance of R5 tropic virus and for tropism switching respectively. 
We conclude that R5 virus more efficiently causes productive infection in its target cells 
and this gives it a replication advantage until those target cells are depleted. We 
conclusively show that initial advantage of R5 virus does not come from the entry 
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AIDS was first recognized as a disease in 1981. The causative agent of the disease 
is Human Immunodeficiency Virus (HIV-1), an RNA virus that infects and kills human 
immune cells. Antiretroviral drugs are now able to efficiently control HIV-1 replication 
and prevent the immune depletion that leads to AIDS but our understanding of the 
disease, and our control over it, remains incomplete. UNAIDS estimated that were 35.3 
million people living with HIV and 2.3 million new HIV infections globally in 2012 [1].  
The virus life cycle has several distinct phases. The first is viral entry into the 
target cell. This is followed by reverse transcription of its RNA. In the third phase the 
new viral DNA integrates into the host’s genome where it waits for the host cell’s 
machinery to produce the encoded viral proteins. The final phases are the assembly, the 
budding/release, and the maturation of the virus particle.  This entire process, on average, 
takes 1.2 days [2].  
The process by which an HIV-1 virion enters a human cell is complex and is still 
not entirely understood. Some studies have used electron microscopy to directly view 
various stages of entry and others have used biochemical techniques and modeling to 
quantitatively analyze the process. While some aspects of HIV-1 entry remain unclear, 
such as the exact number of binding events involved; others, such as the viral entry 
machinery and the basic order of events, have been well defined [3]. During viral 
development, envelope glycoproteins (Env) are produced and assembled into trimers 
(commonly called spikes) that protrude from the surface of the virion [4-8]. Each trimer 
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consists of three sets of noncovalently associated subunits, gp120 and gp41. Thus, spikes 
are homo-trimers composed of three hetero-dimers [9,10].  
The first step in the entry process is viral attachment; here the virus’s gp120 
subunits bind to CD4 molecules on the surface of a host cell [11-15]. This binding 
induces a conformational change within the entry spike that activates the gp120s for 
coreceptor binding [16-24]. In the next step, the activated gp120 binds either the host 
cells CCR5 or CXCR4 chemokine receptors, which both function as coreceptors for HIV-
1 [25-27]. This coreceptor binding causes the gp41 subunits to insert into the host cell 
membrane which initiates the fusion of the viral and cellular membranes.  
The entry step of the HIV-1 life cycle is particularly significant to those 
investigating the difference between the HIV-1 tropisms.  HIV-1 is divided into two 
varieties, called tropisms, based on the molecules it uses to enter a target cell. Current 
nomenclature classifies an HIV-1 isolate as R5 tropic if it uses the CCR5 co-receptor to 
enter a host cell, X4 tropic if it uses the CXCR4 coreceptor, and dual tropic (X4R5) if it 
can utilize either coreceptor for entry [28].   
While there is no single DNA sequence that determines tropism, sequence 
analysis algorithms can be used to predict tropism with accuracies reaching 80-90% [29]. 
Coreceptor usage is primarily determined by the second and third variable loops (V2 and 
V3) of the gp120 subunit [30-33] and positively-charged amino acids at positions 11 and 
25 within V3 are strongly associated with X4 tropism [34, 35]. However, while the 
genotypic differences certainly cause the phenotypic differences, the tropism 
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classification of a virus is a phenotypic observation and functional assays provide the 
most reliable assessment of coreceptor usage.  
While similar in sequence, R5 and X4 viruses behave differently in vivo and the 
phenotypic differences extend beyond the coreceptor preferences that define them. In the 
acute phase of infection, R5 viruses usually predominate [36-42]. Even if the source 
patient has both R5 and X4 tropic viruses, R5 is normally the only viral variant detectable 
in the recipient [34-37]. This is widely documented and most commonly attributed to the 
bottle nose effect that mucosal membranes have on the incoming virus population.  
However, R5 selective transmission has been documented not only in intravaginal 
transmission cases but also in intravenous transmissions, in both Simian 
Immunodeficiency Virus (SIV) lab experiments and human needle stick case studies [43-
45].  
The second phenotypic difference between the two tropisms emerges 
predominantly in advanced stages of the disease. In what appears to be a natural result of 
disease progression, approximately 50% of HIV-1-infected patients experience a tropism 
switch where X4 virus emerges and then takes over, out competing the R5 virus. Much 
like the R5 tropic dominance in early infection, the reason why X4 virus often emerges 
and dominates in advanced stages of the disease remains a mystery. Interestingly, the 
emerging X4 virus most commonly is not an archived virus that surfaces from a latent 
reservoir. Instead, each patient’s virus evolves and transitions through a dual tropic state 
to become X4 tropic [46]. Tropism switching is of particular interest clinically because 
the transition correlates with increased morbidity and mortality [47, 48]. Yet, while the 
effect a tropism switch has on a patient’s overall immune system is clear, Sodroski, et al., 
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show that the cytotoxic effects of R5 and X4 viruses on individual cells are the same 
[49].  
The reduced transmissibility of X4 virus and its correlation with disease 
progression suggest that there are fundamental, biological differences between X4 and R5 
tropic viruses. The most obvious difference is the one that defines tropism, coreceptor 
usage during the entry process. But the coreceptors themselves are merely tools that the 
virus uses to gain entry into a cell. Thus, more information is needed to explain the 
phenotypic differences between the tropisms.  
Closely examining the entry mechanism may help solve some of the mystery 
surrounding phenotypic tropism differences. The stoichiometry of binding, for both CD4 
and the coreceptors CXCR4 and CCR5, is still under debate [50].  In chemistry, 
stoichiometry refers to the relative quantities of reactants and products; in HIV-1 entry it 
refers to the number of spikes, or gp120 subunits with-in a spike that must bind a 
corresponding number of receptors or coreceptors on the host cell surface. One key 
feature of a virion is how many functional envelope (Env) entry spikes it has on its 
surface; this parameter is commonly called nt. Likewise, T is the minimum number of 
spikes required for viral entry. These two terms are key to understanding the 
stoichiometry of neutralization because drugs or antibodies must neutralize nt  - T +1 
trimers in order to render a virion non-infectious.  This is commonly referred to as the 
stoichiometry of virion neutralization [51]. The other key quantitative molecular aspect 
we must look at is the stoichiometry of trimer neutralization. This refers to how many 
gp120 subunits within a trimeric spike must be neutralized in order to impede a spike’s 
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activity.  If R5 and X4 virus differ in any of these parameters it may influence their 
relative entry efficiency.  
There are factors, beyond the molecules used in the entry process, which are also 
relevant to the differences between tropism phenotypes. In addition to entry efficiency, 
target cell availability, target cell activation state, and negative external pressures can 
affect viral reproductive rates.  
A wider range of cell expresses CXCR4 than CCR5. Both naive and memory cells 
express the X4 virus coreceptor while only memory cells express CCR5. While R5 virus 
dominates in early infection despite this fact, the expanded target cell population of X4 
virus may account for the increased morbidity seen after tropism switching.  The 
phenotypes could also be related to the type of cells the viruses infect; or the use of a 
specific chemokine coreceptor could cause a change in host cell signaling or activity. 
Targeting activated cells, or activating target cells, could increase the relative probability 
that an entry event yields a productive infection. Or, an activated cell may more 
efficiently produce the viral proteins and thus yield a larger viral burst size per infected 
cell.  
Negative pressures may also play a role in R5’s initial dominance. A selective 
pressure could disfavor X4 viral replication in early infection. It is well known that the 
cytotoxic lymphocyte response partially limits viral replication [52-57] and it is possible 
that cells expressing CXCR4 could present antigen earlier or more efficiently [58]. If the 
immune system exerts more control over X4 virus than R5 virus, R5 virus would have a 
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replication advantage in early infection [58,59]. Then, in later stages of the disease, 
severe immune impairment could allow for the tropism switch [60].  
In summary, HIV-1 infection is still a relevant world health issue and tropism 
switching leads to significant increases in morbidity and mortality. Yet, while much is 
known about the role that coreceptors play in the viral entry mechanism, the link between 
the molecules used for cell entry and the pattern of R5 dominance followed by X4 
takeover is unclear. This thesis will investigate several factors that have the potential to 











To infect a target cell, HIV-1 must first attach to the cell and then initiate the 
fusion of the viral and cellular membranes [61]. For this purpose, HIV-1 utilizes envelope 
(Env) glycoproteins which protrude from the surface of the virus. These glycoproteins are 
assembled as trimers which are visible in electron micrographs and appear as spikes on 
the surface of the virion. Each spike is composed of three sets of the non-covalently 
associated Env subunits, gp120 and gp41 [62].  In the entry process, gp120 subunits first 
attach to the host cell CD4, and then these CD4-activated gp120 subunits bind to 
chemokine receptors, either CXCR4 or CCR5, which function as co-receptors for HIV-1 
[26, 27, 63, 64]. However, the stoichiometry of this process is incompletely understood. 
Important unanswered questions include: how many spikes must attach to CD4 
molecules, how many must bind to coreceptors, and how many subunits per spike must 
participate in the entry process? These quantitative aspects of viral entry are relevant to 
the development and dosing of entry inhibitors as well as to vaccine design.  
 
Current nomenclature classifies an HIV-1 isolate as R5 tropic if it uses the CCR5 
co-receptor to enter a host cell, X4 tropic if it uses the CXCR4 coreceptor, and dual tropic 
(X4R5) if it can utilize either coreceptor for entry [28].  Both X4 and R5 tropic gp120 
subunits bind CD4 with a Kd of 4 nM but they bind their respective coreceptors with 
different strengths. R5 gp120 binds CCR5 with a Kd of 4-15 nM while X4 gp120 binds 
CXCR4 with a Kd of 200-500 nM. X4R5 gp120 has a reduced ability to bind both 
coreceptors [65-69]. Target cell prevalence also differs for X4 and R5 tropic forms of 
HIV-1 [70]. It is possible that viruses with different tropisms require different numbers of 
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Env spikes to mediate entry or that disabling subunits within a trimer has different effects 
on X4 vs. R5 tropic viruses.  
 
Electron microscopic studies show multiple entry spikes contacting the target cell 
at the same time, but these studies cannot reveal how many of the spikes are functional 
nor how many are actively involved in the fusion process [71]. Molecular experiments, 
which commonly involve measuring the relative infectivity of virions carrying a mixture 
of wild type and mutant gp120 subunits, provide a way to analyze the role that individual 
Env spikes and their subunits play in the HIV-1 entry process. However, as table 1-1 
illustrates, these experiments have yielded conflicting results [51, 72-77]. This is mostly 
due to the different assumption each investigator makes while modeling and to sparse 
data for infectivity curves. Despite the efforts of several investigators, there is still no 
consensus regarding the quantitative aspects of CD4 or coreceptor binding. Multiple 
mathematical models have been used to describe the biophysical aspects of the entry 
process, but few of these models have been directly compared. In this study, we present 
two models that each use only three variables and make no assumptions about the number 
of functional Env spikes a virion presents. Using these models and new experimental 







Mathematical models have frequently been used to estimate the stoichiometric 
parameters of HIV-1 entry [51, 72-79]. The basic equation that describes the relationship 
between relative infectivity (
 
 




a=0 then the subunits function independently and a spike loses one third of its functional 














infectivity curves, we compared the virus preparations made with and without mutant 
DNA. Figure 2C shows that for both Yu2 and HXB2 Envs, virus preparations generated 
with equal amounts of wild type vector show reduced infectivity if mutant vector is also 
present. This inhibitory effect is consistent with reduced functional activity of mixed 
trimers containing both wild type and mutant Env subunits.  
Mutations affecting coreceptor binding 
We first explored the effects of including gp120 subunits that were defective in binding 
to the CXCR4 (X4) or CCR5 (R5) coreceptors. The mutant X4 tropic virus used was 
incapable of supporting virus entry due to a single amino acid substitution (R308L) in the 
V3 region, and the equally deficient R5 tropic mutant virus had two mutations 
(R315G/L317S) in the V3 loop [75]. Figure 3A shows the relative infectivity curves of 
chimeric virus preparations including these mutant gp120 subunits [81]. Infections were 
carried out in primary CD4+  T lymphoblasts. As illustrated in Figure 3A, chimeric 
viruses with a fraction of coreceptor binding-deficient gp120 subunits showed reduced 
infectivity. The degree of reduction was similar for representative R5 and X4 tropic 
viruses.  
Mutations affecting CD4 binding 
Similar experiments were performed with pseudoviruses carrying mixtures of wild type 
gp120 and gp120 with mutations affecting CD4 binding.  The previously described 
gp120 mutation D368R was introduced into X4 tropic (HXB2) and R5 tropic (Yu2) env 
vectors.  This mutation disrupts a key salt bridge involved in CD4 binding [75].  As 
expected, infectivity decreased as the proportion of mutant subunits increased for both 
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HXB2 and Yu2 viruses (Figure 3B) [81].  Interestingly, for any given ratio of wild type 
and mutant plasmids, relative infectivity was marginally lower for viruses with HXB2 
Env than for viruses with Yu2 Env (Figure 3B), meaning that viruses with the R5 Env 
Yu2 may be slightly less affected by the incorporation of CD4-binding deficient gp120 
subunits.  
Fitting relative infectivity curves to mathematical models of the HIV-1 entry process 
and determining best fit 
As discussed above, the shape of the relative infectivity curves reflects the stoichiometry 
of molecular interactions necessary for HIV-1 entry (Figure 1). Using the equations 
described above, we generated theoretical relative infectivity curves for all combinations 
of the variables: 
 
 




 We determined the theoretical curves’ goodness of fit by calculating the 
residual sum of squares. To generate confidence intervals we used 10,000 bootstrap 
samples per experimental data set. Each of the nine points on each new curve was 
individually generated by randomly sampling a population of relative infectivity (RI) 
values that had the same mean and standard deviation as the corresponding experimental 
data point. Then, we determined which theoretical curve best fit each bootstrap sample. 
To generate a 95% confidence interval we included sets of best-fit parameters in 
descending order of frequency until at least 95% of bootstrap samples were accounted 
for. Supplemental Table 1-1 lists all of the theoretical curve parameters in the 95% 
confidence interval.  
Because there is experimental variation, and because the number of spikes per 
virus (nt) may also very, our 95% confidence interval includes many theoretical set of 
parameters. Thus, for ease of comparison, table 1-2 lists the stoichiometric parameters for 
the eight theoretical curves that best matched the experimental curves in Figure 3. The 
table also shows the fraction of bootstrap cases that fit to each of those top eight 
parameters sets and how much of the total bootstrap parameter distribution the top eight 
best fits account for. In the CD4 R5 data set, all parameter sets that fall in the 95% 
confidence interval are listed in table 1-2. In fact, 9,044 out of 10,000 of the best fit 
curves (for CD4 R5) had nt=2 and T=1 values. The other data sets had more variation and 
thus the top eight most common results represent smaller percentages of the 10,000 





Figure 4 illustrates the curves from each model, incremental (a) and discrete (S), which 
best matched each of the four experimental data sets. In all of the data sets analyzed, the 
incremental (a) model gave better fits than the discrete (S) model. This may indicate that 
entry spike function is not an all or none process and that an incremental model is more 
accurate.   
Best fitting stoichiometric parameters 
The most striking result is that entry appears to only require one or two functional spikes. 
As seen in Figure 1, the number of spikes required for entry (T) has a large impact on the 
shape of a theoretical relative infectivity curve. Figure 1-5 is a graphical representation of 
the data in supplemental table 1-1. Each bubble on the plots represents a parameter pair 
(nt, T) and the size of the bubble is proportional to the fraction of bootstrap samples that 
parameter pair fits. This analysis shows that very low values of T most frequently 
generated theoretical curves that matched the experimental data.   Similarly, our better 
fitting model, the incremental (a) model, suggests that the number of functional 
spikes/virion (nt) is also low (2-4) (Figure 1-5 A-D).  
For coreceptor binding, both HXB2 (X4) and Yu2 (R5) viruses consistently 
utilize only one or two entry spikes. For YU2 entry into primary CD4+  T cells, our 
experimental results are consistent with a model in which a single functional spike is 
sufficient for entry and within that spike there is a moderate level of subunit 
interdependence. The HXB2 coreceptor binding data matches a model in which either 
one or two spikes are necessary.  
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During the CD4 binding stage of the entry process, HXB2 viruses again appear to 
require only one or two spikes to attach to the target cell while YU2 more clearly requires 
only one. It is interesting to note that if two spikes are engaged, then fewer active 
subunits per spike are required.  
According to the discrete (S) model, there is no difference between HXB2 (X4) 
and YU2 (R5) virus entry stoichiometry. While the HXB2 and YU2 parameter values in 
the confidence intervals of the incremental (a) model do overlap, HXB2 (X4) virus seems 




In this paper, we present experimental relative infectivity curves which elucidate 
the stoichiometry of CD4 and coreceptor binding during HIV-1 entry.  Several previous 
reports have also investigated the entry stoichiometry HIV-1 [51, 72-78].  However, it is 
difficult to directly compare the results of our study with those of other studies due to 
differences in experimental design and modeling assumptions. Our study, however, has 
several strengths; each relative infectivity curve was generated with nine different 
pseudovirus preparations carrying different ratios of wild type to mutant gp120 subunits. 
Because of the number of points per curve, our analysis has substantial predictive power 
that enables us to use equations with three variables. In addition, we used two different 
types of mutants (specific to either CD4 or coreceptor binding). Table 1-1 compares nine 
stoichiometry studies, their assumptions, methods, and experimental findings.  Figure 1-6 
compares our experimental data with the theoretical curves that correspond to some of 
the parameters suggested by other groups in table 1-1.  
A striking finding in the present study is the low number of functional spikes per 
virion (nt).  Other authors have reported similar observations but the results have been 
controversial [74-77].  One reason for the controversy is that electron tomography studies 
appear to present a different picture. They show more than 1-3 spikes on the surface of a 
virion, and they show HIV-1 Env trimers clustering together on the virion surface to form 
“entry claws” [71]. An alternate interpretation of nt is that each “entry claw” has only two 
or three functional spikes and the clustering of spikes serves to increase the probability 
that the minimum number of functional Env trimers will contact a cell.  Additionally, a 
virus is roughly spherical, and spikes that are not positioned or grouped close enough to 
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the site of cell contact may not be relevant to the entry process. Thus our finding that nt is 
low may not mean that there are only 2-3 entry spikes on a virion, but rather that there are 






Our study confirms that HIV-1 entry requires only one or two functional Env 
entry spikes. It also concludes that an individual virion, on average, has either two or 
three spikes on its surface that are both functional and able to simultaneously contact a 
target cell. In addition, our analysis shows that Env trimers may function with fewer than 
three active subunits. Subunit interaction is best modeled using an incremental variable, 
and this indicates that subunit and entry spike function is not an all or none process. 
These observations together do not paint an optimistic picture for vaccine development; 
in order to disable a virion, a drug or antibody needs to bind nearly all of the subunits on 
all of the Env spikes. Finally, our analysis indicates that, at least in reference to entry 
stoichiometry, there is at most a minimal biophysical difference between HXB2 (X4 
tropic) and Yu2 (R5 tropic) viruses. The collections of best fit parameters for each virus 






We used a total of four different env mutants to make chimeric viruses that express both 
wild type and mutant gp120. Previously characterized mutations that prevent binding to 
CD4 (D368R) or to coreceptors (R308L or R315G/L317S) [19] were introduced into the 
reference isolates HIV-1HXB2 (X4 tropic) and HIV-1Yu2 (R5 tropic) using the Quick 
Change Sight–Directed Mutagenesis Kit (Invitrogen, Grand Island, NY). While the 
reference isolates express the entire gp160 protein, in this paper we discuss the results in 
terms of gp120 because only the gp120 portion is affected by the mutations and is 
involved in the binding events of interest.  
Generating Chimeric Virus 
Relative infectivity assays were performed with pseudotyped virions that carry 
heterotrimers of HIV-1 Env proteins composed of wild-type gp120 subunits and gp120 
subunits that are defective in either CD4 or coreceptor binding. The assembly and virion 
incorporation of such heterotrimers has been confirmed previously [74, 79, 80].   We 
produced these chimeric pseudotyped viruses, which are capable of only single-round 
infection, as previously described [56].  Briefly, we transfected HEK293T cells with a 
GFP-tagged, Env-defective HIV-1 proviral vector (pNL43- E-EGFP) and either with a 
wild type HIV-1 Env expression vector (HIV-1HXB2 or HIV-1Yu2) or with a mixture of 
wild type and mutant Env expression vectors.  By varying the ratio of wild type and 
mutant DNA in the transfection mixture, we controlled the relative abundance of wild 
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type and mutant gp120 subunits in the viral entry spikes. Nine ratios of wild type env 
DNA: mutant env DNA were used, ranging from 9:1 to 1:9.  Transfections were carried 
out using Lipofectamine 2000 (Invitrogen, Grand Island, NY) according to the 
manufacture's protocol.  The media was replaced six hours after transfection, and cells 
were incubated at 37ºC for an additional 48 hours before the virus containing supernatant 
was added to target cells.  
Single-round relative infectivity assay 
We used a modified single-round infectivity assay to assess the effect of mutant Env 
subunits on infectivity as previously described [65]. Briefly, peripheral blood 
mononuclear cells were obtained from healthy blood donors by Hypaque-Ficoll gradient 
centrifugation and then activated with phytohemagglutinin (0.5 µg/ml) and interleukin-2 
(100 U/ml) for 3 days. CD4+ T cells were isolated by negative selection using antibody 
coated magnetic beads (Miltenyi, Bergisch Gladbach, Germany) and seeded into a 96-
well plate at 1 105 cells per well in RPMI1640 supplemented with 10% fetal bovine 
serum, interleukin-2 (100 U/ml) and cytokine-rich supernatant. Cells were infected using 
fresh pseudovirion preparations. To each well, 5-20 µl of virus containing supernatant 
was added (sufficient to produce 1-20% infection) and cells were infected by 
spinoculation at 1,200g, 30°C for 2 hours and further incubated at 37°C for 3 days.  All 
experiments were done in triplicate with cells from at least three different donors, and 
virus from at least three different preparations.  
After the 3 day incubation, cells were washed, resuspended, and fixed with 3% 
formaldehyde. We quantified infectivity as the percentage of GFP+ cells by FACS 
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analysis (FACS Calibur, BD Bioscience) [82]. All replicates, not means or medians, were 
used in the curve matching and statistical analysis. All healthy blood donors gave their 
written informed consent, and the study was approved by the Institutional Review Board 
of Johns Hopkins University. 
Western blots 
For the analysis of HIV-1 gp120 expression, 293T cells were transfected as described 
above with constant amounts of NL43 DNA and varying amounts of vectors containing 
either wild type or mutant env. After 48 hours of virus production time, the HIV-1 rich 
supernatants were collected without disturbing the 293T cells. Samples were prepared 
with NuPAGE LDS sample buffer according to manufactures instructions (Invitrogen, 
Grand Island, NY ) and 40ul of each was loaded and electrophoresed on a NuPAGE 4-
12% Bis-tris gell (NOVEX, Grand Island, NY) and then transferred to an Immun-Blot 
PVDF membrane (Bio Rad, Hercules, CA). The blots were first probed with a primary 
antibody to HIV-1 gp120 (abcam, Cambridge, UK) and then a horseradish peroxidase-
conjugated rabbit anti- goat antibody was added.  The secondary antibody was detected 
through autoradiography using enhanced chemiluminescence.  
Curve matching 
After FACS analysis, the percent relative infection (
 
 
) value for each chimeric virus 
(nine virus preparations per curve, each with a different ratio of mutant and wild type 
gp120 subunits) was calculating by normalizing the percent infection to the infectivity 
level of the wild-type virus. Then, a Matlab version 7.1 (TheMathWorks) program was 
used to generate theoretical curves for all combinations of the following variables within 




30); T, the number of spikes required for entry (range T = 1-30), and either a, a measure 
of subunit interdependence (a continuous variable, range a = -0.5-1, calculated at 0.1 
intervals); or S, a measure of the ability of individual subunits to compensate for each 
other (a discreet variable with possible values 1, 2, 3). The shape of a relative infectivity 
curve reflects the stoichiometry of the biological process, and altering any of these 
parameters changes the shape of the predicted curve (Figure 1). The program compared 
each theoretical curve to each experimental 
 
 
 curve and generated a goodness of fit 
statistic.  Python was used to do the bootstrapping that generated the confidence intervals 
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Table 1-2:  The stoichiometric parameters yielding the best fitting theoretical relative 
infectivity curves. The % column shows the fraction of the bootstrap parameter 
distribution that each individual set of parameters represents.  The Total % column shows 
how much of the total bootstrap parameter distribution the top eight best fits account for.  
  Incremental “a” model Discrete “S” model 









2 1 0.8 29%  3 1 1 26%  
2 1 0.7 22%  5 3 2 13%  
3 2 0.4 14%  3 2 2 10%  
3 2 0.5 12% 87% 2 1 1 9% 76% 
2 1 0.6 5%  4 1 1 9%  
3 2 0.6 5%  6 4 2 5%  
4 3 0.5 1%  4 2 2 4%  
Coreceptor R5 
2 1 0.6 20%  4 2 2 15%  
2 1 0.5 17%  5 2 2 8%  
2 1 0.7 16%  3 1 1 8%  
2 1 0.4 10% 76% 2 1 2 7% 57% 
2 1 0.8 5%  4 1 1 7%  
2 1 0.3 5%  3 1 2 6%  
3 2 0.4 2%  6 3 2 6%  
CD4 X4 
3 2 0.4 19%  3 1 1 24%  
3 2 0.5 15%  3 2 2 11%  
3 2 0.3 13%  2 1 1 11%  
3 2 0.6 8% 70% 4 1 1 8% 70% 
2 1 0.8 6%  5  3 2 6%  
3 2 0.2 5%  6 4 2 5%  





2 1 0.5 31%  4 2 2 25%  
2 1 0.6 29%  5 2 2 12%  
2 1 0.4 16%  3 1 2 8%  
2 1 0.7 10% 96% 5 1 1 7% 70% 
2 1 0.3 4%  4 1 1 7%  
  3 2 -0.1 3%  6 1 1 6%  







Figure 1-1. Theoretical relative infectivity curves generated using various 
combinations of HIV-1 entry stoichiometric parameters. The relative infectivity 
curves representing the results from theoretical systems with various stoichiometric 
parameters. The y-axis is the relative infectivity or the virus and the x-axis is the fraction 
of mutant DNA used is virus generation (Pf). The equations were solved for fractions of 
mutant DNA from 0 to 1 at 0.1 intervals and graphed as solid lines. A: The effect of 
varying nt. In this example, nt =1-5, T=1 and S=2. B: The effect of varying T. The nt 
values are held constant at 5 and T ranges 1-5. C and D: The effect of altering S and a. 







Figure 1-2. Immunoblots and relative infectivity curve illustration gp120 production 
and incorporation. A and B: Western blots showing the gp120 band. Equal amounts of 
virus containing supernatants were loaded. Viruses were generated using 0.6 µg of pNL4-
3Δenv DNA and the indicated amounts of expression vectors for the Env proteins from 
HIV-1Yu2 (A) or HIV-1 HXB2 (B). C: Relative infectivity of virus preparations made 
with equal amounts of wild type Env expression vectors, with or without mutant Env 
expression vectors. Results are expressed as percent of maximal infection achieved with 






Figure 1-3. Relative infectivity curves comparing HIV-1HXB2 (X4) and HIV-1Yu2 
(R5) viruses. A and B: Relative infectivity curves, the fraction of mutant DNA indicated 
was used in virus production. A: HIV-1Yu2 R315G/L317S mutant or HIV-1HXB2 







Figure 1-4. Relative infectivity curves demonstrating the fitting of the theoretical 
models. Experimental relative infectivity data for HXB2 (A, C, squares) and Yu2 (B, D 
,diamonds).Virus preparations made with increasing fractions of mutant vectors encoding 
Env protein defective in coreceptor binding (A, B, solid symbols) or CD4 binding mutant 
(C, D, open symbols). Experimental data are compared to the theoretical relative 
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infectivity curves (colored lines) from the incremental (red) or discrete (blue) models that 
best fit the experimental data. (A) HIV-1HXB2 R308L mutant, incremental model: nt=1 
T=1 a=0.3; discrete model: nt=2 T=1 S=1. (B) HIV-1Yu2 R315G/L317S mutant, 
incremental model: nt = 2, T = 2, a = -0.3; discrete model: nt = 3, T = 1, S = 1. (C) HIV-
1HXB2 D368R mutant, incremental model: nt= 0.3; discrete model: nt = 3, T = 1, S = 1. 
(D) HIV-1Yu2 D368R mutant, incremental model: nt= 1, T = 1, a = -0.2; discrete model: 











Figure 1-5 Bubble graphs illustrating the best fitting nt and T values. Each point on a 
graph represents a parameter pair with nt on the x-axis and T on the y-axis. The size of 
the point is proportional to the fraction of bootstrap samples that parameter pair fit best. 
Graphs A-D show the fitting results from the incremental (a) model and graphs E-H show 
the discrete (S) model. Supplemental table 1-1 lists the values presented on these graphs 






Figure 1-6. Theoretical curves matching parameters listed in Table 1-1. The green 
line with error bars is the CCR5 binding mutation in Yu2 line from Figure 1-3 A.  The 
blue red and purple lines are the theoretical curves that our model generates using a few 
of the parameters predicted by other groups who began their calculation with an 




Supplemental Table 1-1 A list of all the bootstrap parameter sets that fall within a 95% 
confidence interval. The column “# best fits” is the number of times, out of 10,000 trials, 
that a set of parameters best fit a bootstrap generated experimental data set.  
 
           CXCR4 binding mutation in HXB2 
 
CCR5 binding mutation in YU2 
   nt T a #best fits 
 
nt T a #best fits 
   2 1 0.8 2872 
 
2 1 0.6 2011 
   2 1 0.7 2225 
 
2 1 0.5 1696 
   3 2 0.4 1383 
 
2 1 0.7 1642 
   3 2 0.5 1211 
 
2 1 0.4 1033 
   2 1 0.6 468 
 
2 1 0.8 509 
   3 2 0.6 458 
 
2 1 0.3 470 
   4 3 0.5 98 
 
3 2 0.4 214 
   2 1 0.9 62 
 
2 1 0.2 184 
   3 2 0.7 52 
 
3 2 -0.1 175 
   29 28 0.9 52 
 
3 2 0.5 174 
   2 1 0.5 40 
 
3 2 0 136 
   29 28 0.5 36 
 
3 2 -0.2 115 
   28 27 0.5 31 
 
3 2 0.1 101 
   22 21 0.4 31 
 
3 2 0.6 70 
   20 19 0.4 29 
 
2 1 0.1 65 
   27 26 0.5 28 
 
3 2 -0.3 63 
   29 28 0.6 26 
 
3 2 0.3 51 
   24 23 0.4 25 
 
3 2 0.2 40 
   3 1 0.9 24 
 
5 1 0.9 36 
   28 27 0.7 23 
 
4 1 0.9 27 
   26 25 0.4 23 
 
3 1 0.7 27 
   28 27 0.6 22 
 
4 1 0.8 26 
   27 26 0.4 22 
 
3 1 0.8 24 
   29 28 0.4 22 
 
6 1 0.9 21 
   21 20 0.4 21 
 
3 1 0.6 20 
   20 19 0.5 21 
 
3 2 -0.4 20 
   4 3 0.6 21 
 
29 28 0.9 18 
   28 27 0.4 20 
 
4 2 -0.1 18 
   29 28 0.8 20 
 
4 3 -0.3 18 
   3 2 0.1 20 
 
24 23 0.4 17 
   23 22 0.5 19 
 
9 2 0.8 15 
   24 23 0.5 19 
 
23 22 0.4 15 
   16 15 0.4 18 
 
20 19 0.4 14 
   3 1 0.8 18 
 
29 28 0.7 14 
   17 16 0.4 17 
 
2 1 0 14 
   27 26 0.6 17 
 
25 24 0.4 13 
   
37 
 
25 24 0.4 17 
 
28 27 0.5 12 
   
     
27 26 0.5 12 
   
     
21 20 0.4 11 
   
     
10 2 0.8 11 
   
     
11 2 0.9 11 
   
     
3 1 0.9 11 
   
     
4 3 0.5 11 
   
     
19 18 0.4 11 
   
     
22 21 0.5 10 
   
     
22 21 0.4 10 
   
     
23 22 0.3 10 
   
     
29 28 0.5 10 
   
     
26 25 0.4 10 
   
     
26 25 0.6 10 
   
            
CD4 binding mutation in HXB2 
 
CD4 binding mutation in YU2 
    nt T a #best fits 
 
nt T a #best fits 
   3 2 0.4 1938 
 
2 1 0.5 3138 
   3 2 0.5 1486 
 
2 1 0.6 2850 
   3 2 0.3 1317 
 
2 1 0.4 1633 
   3 2 0.6 812 
 
2 1 0.7 980 
   2 1 0.8 594 
 
2 1 0.3 443 
   3 2 0.2 510 
 
3 2 -0.1 269 
   2 1 0.7 303 
 
3 2 -0.2 183 
   4 3 0.5 178 
 
3 2 0 110 
   4 3 0.4 144 
        29 28 0.9 144 
        3 2 0.1 136 
        4 2 0.6 123 
        4 2 0.5 121 
        4 3 -0.1 102 
        4 3 0 94 
        2 1 0.9 90 
        5 2 0.7 71 
        3 2 0.7 69 
        4 3 0.6 42 
        4 2 0.7 41 
        4 3 -0.2 40 
        2 1 0.6 38 
        20 19 0.4 35 
        5 2 0.8 34 
        24 23 0.4 31 
        28 27 0.7 30 
        
38 
 
16 15 0.5 29 
        4 3 0.1 29 
        27 26 0.4 29 
        3 2 0 29 
        17 16 0.4 28 
        28 27 0.6 28 
        5 4 0.5 26 
        6 3 0.5 26 
        27 26 0.5 26 
        7 3 0.6 25 
        29 28 0.6 25 
        28 27 0.5 24 
        27 26 0.6 24 
        4 2 0.4 24 
        23 22 0.4 23 
        24 23 0.5 23 
        29 28 0.5 23 
        5 4 -0.2 22 
        22 21 0.5 22 
        15 14 0.4 22 
        21 20 0.4 21 
        16 15 0.4 21 
        21 20 0.5 21 
        24 23 0.3 21 
        28 27 0.9 20 
        26 25 0.4 20 
        3 1 0.9 20 
        28 27 0.8 19 
        28 27 0.4 19 
        18 17 0.4 19 
        14 13 0.4 19 
        29 28 0.8 19 
        29 28 0.4 19 
        13 12 0.4 19 
        27 26 0.8 18 
        5 4 -0.3 18 
        29 28 0.7 18 
        22 21 0.4 16 
        12 11 0.4 16 
        25 24 0.4 16 
        23 22 0.5 15 
        27 26 0.7 15 
        11 10 0.4 15 
        
39 
 
19 18 0.4 15 
        25 24 0.6 15 
        17 16 0.5 14 
        5 2 0.6 14 
        
            CXCR4 binding mutation in HXB2 
 
CCR5 binding mutation in YU2 
   nt T S #best fits 
 
nt T S #best fits 
   3 1 1 2629 
 
4 2 2 1529 
   5 3 2 1279 
 
5 2 2 764 
   3 2 2 957 
 
3 1 1 754 
   2 1 1 922 
 
2 1 2 735 
   4 1 1 886 
 
4 1 1 705 
   6 4 2 540 
 
3 1 2 611 
   4 2 2 404 
 
6 3 2 569 
   2 1 2 330 
 
5 1 1 502 
   8 5 2 284 
 
5 3 2 345 
   7 4 2 255 
 
6 1 1 330 
   9 6 2 176 
 
7 1 1 220 
   7 5 2 158 
 
7 3 2 211 
   5 1 1 137 
 
7 4 2 191 
   6 2 1 124 
 
8 4 2 173 
   10 7 2 105 
 
6 2 2 147 
   5 2 1 85 
 
2 1 1 138 
   10 6 2 67 
 
8 1 1 138 
   7 2 1 62 
 
3 2 2 130 
   6 3 2 56 
 
9 5 2 101 
   9 5 2 55 
 
9 4 2 101 
   
     
9 1 1 92 
   
     
8 3 2 85 
   
     
10 5 2 80 
   
     
12 6 2 67 
   
     
11 6 2 67 
   
     
10 4 2 65 
   
     
11 5 2 57 
   
     
10 6 2 51 
   
     
10 1 1 49 
   
     
8 5 2 48 
   
     
4 1 2 46 
   
     
11 4 2 38 
   
     
11 1 1 35 
   
     
9 3 2 34 
   
     
12 5 2 34 
   
     
13 7 2 32 
   
40 
 
     
7 2 2 29 
   
     
12 1 1 28 
   
     
13 6 2 27 
   
     
12 7 2 27 
   
     
10 3 2 22 
   
     
6 4 2 21 
   
     
11 7 2 19 
   
     
14 8 2 18 
   
     
14 7 2 18 
   
     
13 1 1 13 
   
     
8 2 2 13 
   
            
 
CD4 binding mutation in HXB2 
 
CD4 binding mutation in YU2 
    nt T S #best fits 
 
nt T S #best fits 
   3 1 1 2442 
 
4 2 2 2474 
   3 2 2 1141 
 
5 2 2 1194 
   2 1 1 1094 
 
3 1 2 817 
   4 1 1 813 
 
5 1 1 689 
   5 3 2 603 
 
4 1 1 670 
   6 4 2 476 
 
6 1 1 614 
   7 2 1 406 
 
7 3 2 541 
   6 2 1 385 
 
6 3 2 535 
   9 6 2 242 
 
7 1 1 370 
   8 2 1 222 
 
3 1 1 304 
   4 2 2 192 
 
8 4 2 221 
   10 7 2 192 
 
9 4 2 209 
   8 5 2 179 
 
8 3 2 200 
   5 2 1 158 
 
8 1 1 179 
   7 5 2 134 
 
2 1 2 171 
   5 1 1 131 
 
10 4 2 114 
   4 3 2 131 
 
6 2 2 99 
   11 8 2 110 
 
9 1 1 97 
   4 2 1 84 
 
11 4 2 48 
   11 7 2 74 
        2 1 2 73 
        12 8 2 64 
        7 4 2 64 
        13 9 2 60 
        9 2 1 51 






Investigating Possible Causes for R5 Tropism Dominance in 





To attach to and enter a host cell, human immunodeficiency virus type 1 (HIV-1) 
must bind a CD4 receptor on the target cell surface. After the virus attaches to the CD4 
molecule, it then binds a coreceptor to complete the entry process. Viruses that use the 
chemokine coreceptor CCR5 are commonly called R5 tropic viruses and those that use 
CXCR4 are named X4 tropic viruses [28]. While much of the sequence difference 
between the viral genomes of R5 and X4 tropic virus has been examined and described, 
we lack a definitive explanation for the virus’s phenotypic differences.  
Usually, new infections arise from only one or very few genotypic species [83-
40]. Interestingly, the transmitter founder virus is almost always R5 tropic; this is true for 
sexual transmission, parenteral, and vertical transmissions [39]. After infection is 
established, the virus evolves and diversifies quickly, driven by its high rate of 
replication, mutation, and recombination [86-88]. In approximately 50% of HIV-1 
subtype B infected patients, in late stages of disease, the virus evolves away from its 
initial CCR5 binding preference and switches to CXCR4 usage [28, 77, 89-93]. This 
switch in dominant viral tropism is associated with accelerated CD4+ T cell depletion as 
well as increased morbidity and mortality [35, 82, 94-99].  
Any hypothesis that aims to explain  the phenotypic differences between R5 and 
X4 HIV-1 virus must account for both the initial R5 dominance and the switch to X4 (is 
seen in ~50% of patients). One of the most common explanations, preferential 
transmission, falls short here. It cites random mutation as the cause of the latter and the 
observed bottle neck effect that passing through a CCR5 coreceptor rich mucosal 
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membrane during sexual transmission has on an HIV-1 virus population as the cause of 
the former. But the preferential transmission explanation is undermined by the fact that 
R5 dominance is transmission route independent [36, 27, 100, 101]. Infections 
originating from intravenous drug use and blood transfusions also show R5 dominance 
[39], as do IV infected monkeys [102] and needle stick victims [45, 103].  
Another potential explanation, the immune-control hypothesis, posits that the 
immune system exerts more control over X4 virus than R5 virus, and thus R5 virus has a 
replication advantage in early infection [58, 59]. Then, a severe immune impairment 
allows for the tropism switch [60]. Callaway, et al., confirmed the theoretical potential of 
this hypothesis with a complex model of viral dynamics that predicts tropism switching 
in a manner that is consistent with experimental and clinical observations [104]. Their 
analysis shows that a strong immune system with enhanced ability to recognize X4 virus 
is sufficient to select for an R5 virus while a weak immune system favors X4 
propagation. Additionally, Bonhoeffer, et al., conclude that the ratio of nucleotide 
substitutions per synonymous site, (ds) to non-synonymous site (dn) is significantly lower 
in X4 tropic strains [58]. Low ds/dn ratios indicate strong diversifying selection for amino 
acid change and Bonhoeffer, et al., note that their results could be explained by an 
immune system that more strongly affects X4 virus [58]. It is well known that the 
cytotoxic lymphocyte response partially limits viral replication [52-57] and it is possible 
that cells expressing CXCR4 could present antigen earlier or more efficiently [58]. 
Supporting experimental evidence for this hypothesis comes from two animal studies 
which implicate the cytotoxic lymphocyte (CTL) as the component of the immune system 
specifically controlling X4 tropic virus [102, 105].  
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A third theory explains R5 dominance and tropism switching with a combination 
of differing replication rates and target cell availability. This hypothesis posits that R5 
virus has some replication advantage in early infection that either disappears or is 
outweighed by target cell availability in later infection. Changes in the target cell 
population over time will affect the relative fitness of the viral tropisms. R5 and X4 have 
overlapping but different target cell populations. Because X4 virus has a wider target cell 
range, the relative fitness of X4 virus will as a dominant R5 virus depletes its target cell 
population, [106- 108]. Several mechanisms for R5 virus’s replication advantage are 
possible: (1) R5 virus may have a larger burst size; producing more virus particles per 
infected cell could mean a higher R0. (2) R5 virus may have the ability to enter cells more 
efficiently than X4. This would give R5 a replication advantage until its target cells are 
depleted. (3) R5’s early competitive advantage could be target cell related and come from 
a compartment where cells express CCR5 but not CXCR4. The gut associated lymphoid 
tissue (GALT) could be such a location as it is CCR5 rich and its cells are often the first 
to be depleted regardless of the infection rout [109]. (4) The activation state of the cells 
each virus infects could affect the percentage of entry events that lead to productive 
infection. Naïve CD4+ T cells express CXCR4 while memory CD4+ T cells express both 
CXCR4 and CCR5 [106]. In early infection, memory cells proliferate up to ten times as 
frequently as naive cells and it is only in late infection that the proliferation rates even out 
[110]. Thus, in early infection, X4 entry is less likely to produce a productive infection 
[101, 111]. In fact, Weinberger, et al., present a mathematical model that concludes that 
an increase in the ratio of the fractions of activated memory and naive CD4+ T cells, as 
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occurs when the CD4+ T cell concentration drops below a threshold, is sufficient to 
produce a tropism switch [112].  
 To further investigate the immune-control hypothesis and the replication 
rate/target cell availability hypothesis we conducted a range of experiments with a panel 
of viruses of varied tropisms.  We explore CTL suppression of infection as well as burst 






Tropism characterization: Traditionally, when studying viral tropism, standard 
reference strains like YU2 (R5) and HXB2 (X4) are used. But because the sequences of 
these strains also differ in areas not associated with coreceptor specificity, the 
comparison is not perfectly controlled. In order to focus on tropism specific differences 
we used a series of viral Env clones, ranging from R5 to X4 tropic, that all came from the 
same patient [113].  The clones were longitudinally collected by Shankarappa, et al., 
from their study patient number five whose virus was originally R5 tropic and then 
switched to X4 tropic at 5.67 years post infection [77, 114]. These Env expressing 
plasmids were kindly donated to us by Coetzer, et al. 
The tropisms of the six clones used in this study are listed in Figure 2-1A, along 
with their numerical designation from Shankarappa, et al., and the year post infection that 
they were isolated. Figure 1B shows the relative inhibition of each clone by the 
coreceptor binding drugs AMD3100 (CXCR4) and Maraviroc (MVC, CCR5). The results 
presented here are similar to the characterizations made by Coetzer, et al. Extensive 
sequence analysis of these clones has been conducted previously [113]. For visual 
comparison purposes, Figure 2 shows the variable loop regions, which contribute most to 
the increased diversity at 5.67 years post infection.  
 
Infectivity: Figure 3 shows infectivity graphs for the six viruses in CD4+T cells from two 
different representative healthy donors.  For the same amount of concentrated virus, the 
X4 tropic clones infect more cells than the R5 viruses do. The p24 concentrations of the 
virus preparations were also tested and were all within experimental error of one another 
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(data not shown). Thus, while the X axis is labeled as “Concentrated virus (ul),” the 
volume corresponds to the p24 added.  
The tropism specific differences in infectivity shown here may be attributable to 
coreceptor availability. Figure 4 shows the specific antibody binding capacity of a CD4+T 
cell for CD4, CXCR4, and CCR5 antibodies. This FACS based assay uses a standard 
curve, made from beads with known numbers of antibody binding sights (figure 4B), to 
convert a sample’s mean florescence intensity into antibody binding units. While all of 
the cells express CD4 and CXCR4, only 8.7% of cells express measurable numbers of 
CCR5 coreceptors (figure 4A).  
 
Burst Size: The burst size of a cell infected by one of the six viral clones was calculated 
by first assessing the total p24 output of a well of cells via p24 ELISA and then dividing 
that by the percent of cells with productive infections. Because the difference between the 
individual donors was often larger than the difference between viral clones the data was 
further normalized with the largest burst size of each donor set to one. Figure 5 shows the 
average relative burst sizes of five donors. While there are differences between the viral 
clones, no tropism related pattern appears.  
 
Suppression: In the suppression assays, the variation in infectivity between donors 
persisted and thus we chose to show three individual representative donors instead of an 
average. The left three graphs in figure six show the dose response relationship between 
the percentage of CD4+ T cells infected and the ratio of CD8+ effector cells. CD8+ T cells 
clearly cause suppression of infection, as seen by %GFP. However, this format does not 
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allow for an easy comparison among the six virus types. The calculated levels of 
suppression, shown in the right hand column, are the result of subtracting the percent 
GFP of the CD4’s that were in contact with CD8’s from the CD4 only percent infection, 
and then dividing by the former. There was no correlation between tropism and 
suppression from CD8’s.  
 
 Modeling growth kinetics: Equation 1 describes the rate of change of viral load where 
 
 is the viral load, 
 
 is the number of virus particles an infected cell produces (burst 
size), 
 
 is infected cell death rate, and 
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the single round, in vitro assay viral clearance is not relevant. Equation 2 does not include 












Tropism characterization: Each isolate in this study was affected by only one of the 
two entry inhibitors, AMD3100 or Maraviroc. While including perfectly dual tropic virus 
in the study would have been ideal, it is not surprising that this was not possible. Dual 
tropic virus has a decreased ability to bind either coreceptor [116]. Viral clones with a 
maximum infection capability that was consistently less than 0.5% were not used.  
 
Infectivity: Clinical observations and animal studies indicate that R5 tropic virus is better 
able to establish a productive infection than X4 virus [27, 36, 39, 45, 100-103]. However, 
the data from our in vitro studies seem to contradict that trend. The R5 tropic viruses 
consistently show lower infection levels that the X4 tropic viruses. A plausible 
explanation for the tropism specific differences in infectivity is the relative coreceptor 
availability within our target cell population. As figure 4 shows, all circulating, primary 
isolated, CD4+T cells express CD4 and CXCR4 while only 8.7% express measurable 
amounts of CCR5 coreceptors. Thus the target cell population for R5 tropic virus is much 
smaller than for X4. It is possible that initial infection primarily takes place in a micro 
environment where CCR5 coreceptors are preferentially expressed, such as the GALT 
[109]. But based on our studies, X4 virus and not R5 virus yields higher percent 
infections (%GFP) in our isolated CD4+T cells.  
An additional feature that is important to note in Figure 3 is that while the same 
amount of virus was used for each virus type in each donor, the y axis’s scales are 
significantly different. With this donor to donor variability, graphs of averaged biological 
replicates would show identical trends but with deceptively large error bars.  This issue 
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persists throughout all of the subsequent experiments. The magnitude of difference within 
Figure 2-3A is about 5 fold from highest to lowest. In Figure 2-3 B it is about 4 fold. The 
differences between values in A and B are also roughly 4-fold. Because the pattern is 
precisely the same within each CD4+ T cell donor, the difference among the viral strains 
is attributable to biological differences in the strains and the differences between A and B 
can be attributed to CD4+ T cell susceptibility. 
Furthermore, to prevent multiplicity of infection we use virus concentrations that 
fall within the linear portion of the titration curve. For the R5 virus clones, this is less 
than 0.5% infection as measured by GFP positivity. Thus, the problem of large inter 
donor variability is compounded by the low levels of infection; both of these factors lead 
to the relatively large error bars seen in many of the figures.  
 
Burst Size: Both a cell’s activation state and the HIV-1 integration site can influence the 
burst size. It is possible that viruses of different tropisms preferentially infect cells with 
different activation states, or they may even alter the activity of the cell as they utilize 
their respective chemokine coreceptors. However, our experimental results show no 
tropism correlated trend in burst size. We do see significant variability in the burst size of 
each virus. Unlike the viral titrations or the suppression data, the burst size graphs have 
two sources of experimental variation. The low infection rates (FACS data) and the 
relatively low amounts of p24 produced (ELISA assay) mean that, when properly 




Suppression: Gag stimulated autologous CD8+ T cells have previously been shown to 
suppress viral infection of CD4+ T cells in vitro [117, 118].   Gag-specific CD8+ T cells 
can target incoming virions and kill cells prior to productive infection [119, 120].  We 
used a suppression assay to determine if a host’s cytotoxic lymphocyte (CTL) response 
exerts a selective pressure. In theory, the CTL response could be more effective at 
controlling X4 tropic virus than R5 virus. This would confirm the immune hypothesis and 
explain why X4 tropic virus dominates late in infection, after the immune system is 
severely depleted.  
However, our data show no evidence of a tropism specific trend. The majority of 
the data was gathered using HIV+ HAART suppressed patient cells because only CD8+ T 
cells from HIV+ donors will activate when exposed to gag peptides. These patient cells 
show low levels of infection and only moderate suppression levels (figure 6A B D E). 
Furthermore, proper propagation of error yields large standard deviations; this is due 
primarily to the low infection levels. For example, a sample can be 30% suppressed while 
the total difference in GFP is only 0.05%. Figures 6D and 6E illustrate this experimental 
limitation.  
Figures 6C and 6F show a representative example of a suppression experiment 
using cells from an elite suppressor. These cells have two advantages: the cells are more 
susceptible to infection because the donor is not on HAART and elite suppressors have 
been shown to perform better in suppression assays [121]. Data from elite suppressor 
cells still shows no tropism correlated suppression trends. But here, unlike in the HIV+ 
donor cells, we see enough infection and suppression to be able to recognize the 




Our data supports the hypothesis that credits replication rate and target cell 
availability for R5 virus’s dominance and for tropism switching, respectively. Neither 
CTL suppression nor burst size appears to correlate with tropism, but R5 tropic virus still 
has some kinetic advantage. The simple viral growth modeling done here shows that, in 
our in vitro system, target cell availability is responsible for X4’s higher infection rates. If 
early R5 virus replication primarily took place in location where it did not have a target 
cell disadvantage, potentially the GALT, then it would be more fit than X4 virus [109]. 
We conclude that R5 virus more efficiently enters its target cells, giving it a replication 







  Relative infectivity assays were performed with virions that had patient derived Env. 
We produced these viruses, which are capable of only single-round infection, as 
previously described [122].  Briefly, we transfected HEK293T cells with a GFP-tagged, 
Env-defective HIV-1 proviral vector (pNL43- E-EGFP) and with a wild type patient 
derived HIV-1 Env expression vector.  Transfections were carried out using 
Lipofectamine 2000 (Invitrogen, Grand Island, NY) according to the manufacture's 
protocol.  The cells were incubated at 37ºC for 48 hours before the virus containing 
supernatant was layered onto a 20% sucrose buffer and ultra-centrifuged at 25,000g for 
2h at 4ºC. Viral pellets were then resuspended in RPMI.  
Study Subjects 
Peripheral blood for the isolation of primary CD4+ and CD8+ T cells was obtained from 
HIV-1-infected patients on HAART with undetectable viral loads, from elite suppressors, 
and from healthy donors. All donors gave their written informed consent and the study 
was approved by the Institutional Review Board of Johns Hopkins University. 
Single-round infectivity assay 
 We used a modified single-round infectivity assay to assess the effect of various Env 
tropism on infectivity as previously described [122, 123]. Briefly, peripheral blood 
mononuclear cells were obtained from healthy blood donors by Hypaque-Ficoll gradient 
centrifugation and then activated with phytohemagglutinin (0.5 µg/ml) and interleukin-2 
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(100 U/ml) for 3 days. CD4+ T cells were isolated by negative selection using antibody 
coated magnetic beads (Miltenyi) and seeded into a 96-well plate at 1 105 cells per well 
in RPMI1640 supplemented with 10% fetal bovine serum, interleukin-2 (100 U/ml) and 
cytokine-rich supernatant. Cells were infected using concentrated pseudovirion 
preparations. To each well, 0.5-2 µl of virus was added and cells were infected by 
spinoculation at 1,200g, 30°C for 2 hours and further incubated at 37°C for 3 days [124].   
After the 3 day incubation, primary CD4+ T cells were washed, resuspended, and 
fixed with 3% formaldehyde. We quantified infectivity as the percentage of GFP+ cells 
by FACS analysis (FACS Calibur, BD Bioscience) [122].  
Quantitative FACS 
QFACS was performed using standardized microbeads (QIFIKIT®*, Dako) according to 
the manufacturer’s instructions. The primary antibodies used were purified mouse anti-
human CD4, purified mouse anti-human CD184, purified mouse anti-human CD 195, and 
the corresponding isotype controls, all obtained from BD Biosciences. The kit consisted 
of a mixture of five populations of beads, each of which had a specific number of mouse 
monoclonal antibody (Mab) molecules per bead, and an anti-mouse FITC conjugated 
secondary antibody. Saturating concentrations of primary and secondary antibodies were 
used on the cells, and the beads were processed at the same time and in the same manner 
as the cells. Beads and samples were analyzed by FACS (FACS CantoII), and the data 
were processed using FlowJo software. This enabled us to create a standard curve relating 




 Our suppression assay was adapted from previously described assays [125-127]. PBMCs 
from patients were isolated and cultured in the presence of a mixture of 129 overlapping 
Gag peptides (80 ng/ml for each) (NIH AIDS Reagent Program) and IL-2 (10 U/ml). 
Six days after stimulation, CD8+ T cells were isolated by positive selection using Human 
CD8 Microbeads following the manufacturer’s guidelines (Miltenyi Biotec).  
CD4+ T cells were activated and isolated as described in the Single-round 
infectivity assay section. They were then spinoculated in 5ml conical tubes as described 
[59] at 1,200 × g, 30 ºC for 2 h with one of the six viruses. Cells without virus were 
spinoculated as a negative control. After spinoclulation, CD4+ T cells were washed and 
plated in a 96 well plate at 1 × 105 cells / well in RPMI 1640 supplemented with 10% 
FBS. Stimulated CD8+ T cells were immediately added to the spinoculated CD4+ T cells, 
at specified ratios. The number of CD4+ T cells per well remained constant and the 
number of CD8+ T cells was varied. Wells with only CD4+ T cells (targets alone) were 
used as positive controls. Cells were cultured for 3 days in a final volume of 200 μL of 
non-stimulating media. The cells were then fixed, stained, (CD3 Pacific Blue, CD8 APC, 









Figure 2-1 Tropisms of six patient viruses. A. A table listing the tropism, the isolate 
number and the year post initial infection that the virus was isolated. B. The relative 
inhibition of each virus caused by either the CXCR4 binding entry inhibitor AMD3100, 









Figure 2-2 Sequence alignments of the variable loop regions. The first sequence 
change is highlighted in yellow. If an amino acid changes more than once, its second 







Figure 2-3 Viral titrations. Two representative donors are shown. Percent GFP+ 
(infection level) is graphed versus the volume of concentrated virus. Virus was analyzed 








Figure 2-4 Coreceptor availability. A. The y axis shows the specific antibody binding 
capacity per CD4+ T cell. In this assay, one antibody binding unit corresponds to one 
available receptor or coreceptor. When antibodies specific for CCR5 were used, there 
were two distinct populations of CD4+ T cells, 8.7% expressed CCR5 and 90.4% did not; 
numbers are an average of donors and thus don’t add to 100%. B. Histograms of cells and 
of the standard curve beads are shown along with FACS plots of isolated CD4+ T cells. 







Figure 2-5 Relative burst size. Values shown are the average of five healthy donors. 
The y axis is the p24 present in a well three days after infection (minus day zero p24), 
divided by the number of cells producing virus (%GFP+). For each donor, viral burst size 
was normalized, the largest virus’s burst size being set to 1. Standard deviation was 









Figure 2-6 Suppression assays. Three donors are shown, A/D and B/E are HAART 
patients and C/F is an elite suppressor. Green is the control result from wells containing 
only CD4+ T cells. Blue represents wells with a 1:16 ratio of CD8+ T:CD4+T cells. For 
the red bars the ratio is 1:1. A-C show CD4+ T cell infection levels for each virus. D-F 






Supplemental Table 2-1 
 
Supplemental Table 2-1 Infection data (%GFP) corresponding to Figure 2-3. The 
%GFP values graphed in Figure 2-3 and used in kinetic rate constant (k) calculations. 
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Chapter 3:  




Overall, this work provides evidence against many of the proposed causes for X4 
and R5 virus’s phenotypic differences, but the positive data it produces is vague. R5 virus 
replication does have some kinetic advantage over X4 virus, but this advantage does not 
come from the entry machinery or from the viral burst size. Some other unidentified 
factor, potentially cellular activation, must be responsible.  
Chapter one confirms that HIV-1 entry requires only one or two functional Env 
entry spikes. It also concludes that an individual virion, on average, has between one and 
three spikes on its surface that are both functional and able to simultaneously contact a 
target cell. However, this in depth analysis of the viral entry process failed to find a 
significant biophysical difference between HXB2 (X4 tropic) and Yu2 (R5 tropic) 
viruses. Both tropisms tested appear to have indistinguishable entry stoichiometry.  
Chapter two provides evidence against CTL suppression or burst size playing a 
role in early R5 dominance. The viral growth modeling shows that, in our in vitro system, 
target cell availability is responsible for X4’s higher infection rates. But this does not 
necessarily correlate to early infection in vivo. The most interesting difference between 
the two tropisms discovered here is the infection rate constant; this number comes from 
equation 2 which includes factors for infection rate, burst size and, target cell availability. 
Based on this equation and the data experimentally collected in chapter two, R5 virus has 
a more than two fold replication advantage over some of the X4 viral isolates. If the 
difference in target cell availability during early infection turns out not to 
overwhelmingly favor X4 growth, this kinetic difference could explain R5’s initial 
dominance. In later infection, it possible that the tropism switch is a result of random 
chance or is influenced by changing cellular target populations.  
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Overall, our data supports the hypothesis that credits replication rate and target 
cell availability for R5 virus’s dominance and for tropism switching, respectively. We 
conclude that R5 virus more efficiently causes infection in its target cells and this gives it 
a replication advantage until those target cells are depleted.  
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